High-density lipoproteins prevent the oxidized low-density lipoprotein-induced endothelial growth factor receptor activation and subsequent matrix metalloproteinase-2 upregulation

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 25, Issue 6, 2005, Pages 1206-1212

  Robbesyn, Fanny ^a   Augé, Nathalie ^a   Vindis, Cécile ^a   Cantero, Anne Valérie ^a   Barbaras, Ronald ^a   Negre Salvayre, Anne ^a,b   Salvayre, Robert ^a,b  

^a INSERM   (France)

^b CHU RANGUEIL   (France)

Author keywords

Atherosclerosis; Endothelial growth factors; Lipoproteins

Indexed keywords

2,4 DINITROPHENYLHYDRAZINE; 4 HYDROXYNONENAL; CARBONYL DERIVATIVE; CATALASE; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HIGH DENSITY LIPOPROTEIN; HYDROGEN PEROXIDE; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE 14; OXIDIZED LOW DENSITY LIPOPROTEIN; REACTIVE OXYGEN METABOLITE;

ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CELL ACTIVATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REGULATION; HEART PROTECTION; HUMAN; HUMAN CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

ALDEHYDES; ANTIGENS, CD36; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; CATALASE; CELL LINE; DRUG INTERACTIONS; HYDROGEN PEROXIDE; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MATRIX METALLOPROTEINASE 2; MUSCLE, SMOOTH, VASCULAR; OXIDATIVE STRESS; PROTEIN CARBONYLATION; REACTIVE OXYGEN SPECIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 20144374665     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000164805.73558.80     Document Type: Article

References (47)

1. Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: implication for cholesterol deposition in atherosclerosis. Annu Rev Biochem. 1983;52:223-261.
2. Lusis AJ. Atherosclerosis. Nature. 2000;407:233-241.
3. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999;340:115-126.
4. Witztum JL, Steinberg D. Role of oxidized LDL in atherogenesis. J Clin Invest. 1991;88:1785-1792.
5. Berliner JA, Heinecke JW. The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med. 1996;20:707-727.
6. Hajjar DP, Haberland ME. Lipoprotein trafficking in vascular cells. Molecular Trojan horses and cellular saboteurs. J Biol Chem. 1997;272:22975-22978.
7. Chisolm GM, Steinberg D. The oxidative modification hypothesis of atherogenesis: an overview. Free Radic Biol Med. 2000;28:1815-1826.
8. Assmann G, Nofer JR. Atheroprotective effects of HDL. Annu Rev Med. 2003;54:321-341.
9. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res. 1995;36:211-228.
10. Navab M, Berliner JA, Subbanagounder G, Hama S, Lusis AJ, Van Lenten BJ, Vora D, Fogelman AM. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol. 2001;21:481-488.
11. Libby P. Managing the risk of atherosclerosis: the role of HDL. Am J Cardiol. 2001;88:3N-8N.
12. Calabresi L, Gomaraschi M, Franceschini G. Endothelial protection by HDL: from bench to bedside. Arterioscler Thromb Vasc Biol. 2003;23:1724-1731.
13. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000;103:211-225.
14. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. EGF receptor: mechanisms of activation and signalling. Exp Cell Res. 2003;284:31-53.
15. Moghal N, Sternberg PW. Multiple positive and negative regulators of signaling by the EGF-receptor. Curr Opin Cell Biol. 1999;11:190-196.
16. Gamou S, Shimizu N. Hydrogen peroxide preferentially enhances the tyrosine phosphorylation of EGF receptor. FEBS Lett. 1995;357:161-164.
17. Knebel A, Rahmsdorf HJ, Ullrich A, Herrlich P. Dephosphorylation of receptor tyrosine kinases as target of regulation by radiation, oxidants or alkylating agents. EMBO J. 1996;15:5314-5325.
18. Sue I, Meilhac O, Lajoie-Mazenc I, Vandaele J, Jurgens G, Salvayre R, Negre-Salvayre A. Activation of EGF receptor by oxidized LDL. FASEB J. 1998;12:665-671.
19. Vacaresse N, Vieira O, Robbesyn F, Jurgens G, Salvayre R, Negre-Salvayre A. Phenolic antioxidants trolox and caffeic acid modulate the oxidized LDL-induced EGF-receptor activation. Br J Pharmacol 2001;132:1777-1788.
20. Frank GD, Eguchi S. Activation of tyrosine kinases by reactive oxygen species in vascular smooth muscle cells: significance and involvement of EGF receptor transactivation by angiotensin II. Antioxid Redox Signal. 2003;5:771-780.
21. Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A. The EGF receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer. 2001;8:11-31.
22. Kalmes A, Daum G, Clowes AW. EGFR transactivation in the regulation of SMC function. Ann N Y Acad Sci. 2001;947:42-54.
23. Berk BC. Vascular smooth muscle growth: autocrine growth mechanisms. Physiol Rev. 2001;81:999-1030.
24. Habib AA, Chatterjee S, Park SK, Ratan RR, Lefebvre S, Vartanian T. The EGF receptor engages receptor interacting protein and NF-kB-inducing kinase to activate NF-kB. J Biol Chem. 2001;276:8865-8874.
25. Monaco C, Andreakos E, Kiriakidis S, Mauri C, Bicknell C, Foxwell B, Cheshire N, Paleolog E, Feldmann M. Canonical pathway of NF-kB activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis. Proc Natl Acad Sci USA. 2004;101:5634-5639.
26. Menashi S, Serova M, Ma L, Vignot S, Mourah S, Calvo F. Regulation of extracellular matrix metalloproteinase inducer and matrix metalloproteinase expression by amphiregulin in transformed human breast epithelial cells. Cancer Res. 2003;63:7575-7580.
27. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002;90:251-262.
28. Lijnen HR. Extracellular proteolysis in the development and progression of atherosclerosis. Biochem Soc Trans. 2002;30:163-167.
29. Ikeda U, Shimada K. Matrix metalloproteinases and coronary artery diseases. Clin Cardiol. 2003;26:55-59.
30. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003;92:827-839.
31. Huang Y, Mironova M, Lopes-Virella MF. Oxidized LDL stimulates MMP-1 expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol. 1999;19:2640-2647.
32. Rajavashisth TB, Liao JK, Galis ZS, Tripathi S, Laufs U, Tripathi J, Chai NN, Xu XP, Jovinge S, Shah PK, Libby P. Inflammatory cytokines and oxidized LDL increase endothelial expression of MT1-MMP. J Biol Chem. 1999;274:11924-11929.
33. Robbesyn F, Garcia V, Auge N, Vieira O, Frisach MF, Salvayre R, Negre-Salvayre A. HDL counterbalance the proinflammatory effect of oxidized LDL by inhibiting intracellular reactive oxygen species rise, proteasome activation, and subsequent NF-kappaB activation. FASEB J. 2003;17:743-745.
34. Sullivan SG, Chiu DT, Errasfa M, Wang JM, Qi JS, Stern A. Effects of H2O2 on protein tyrosine phosphatase activity in HER 14 cells. Free Radic Biol Med. 1994;16:399-403.
35. Auge N, Maupas-Schwalm F, Elbaz M, Thiers JC, Waysbort A, Itohara S, Krell HW, Salvayre R, Negre-Salvayre A. Role for matrix metalloproteinase-2 in oxidized LDL-induced activation of the sphingomyelin/ceramide pathway and smooth muscle cell proliferation. Circulation. 2004;110:571-578.
36. Kuzuya M, Kanda S, Sasaki T, Tamaya-Mori N, Cheng XW, Itoh T, Itohara S, Iguchi A. Deficiency of gelatinase A suppresses smooth muscle cell invasion and development of experimental intimal hyperplasia. Circulation. 2003;108:1375-1381.
37. McCall MR, Tang JY, Bielicki JK, Forte TM. Inhibition of lecithin-cholesterol acyltransferase and modification of HDL apolipoproteins by aldehydes. Arterioscler Thromb Vasc Biol. 1995;15:1599-1606.
38. Sangvanich P, Bharti Mackness B, Gaskell SJ, Paul Durrington P, Mackness M. The effect of HDL on the formation of lipid/protein conjugates during in vitro oxidation of LDL. Biochem Biophys Res Commun. 2003;300:501-506.
39. Escargueil-Blanc I, Salvayre R, Vacaresse N, Jürgens G, Darblade B, Arnal J, Parthasarathy S, Negre-Salvayre A. Mildly oxidized LDL induce activation of PDGF β-receptor pathway. Circulation. 2001;104: 1814-1821.
40. Baynes JW, Thorpe SR. Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med. 2000;28:1708-1716.
41. Napoli C, de Nigris F, Palinski W. Multiple role of reactive oxygen species in the arterial wall. J Cell Biochem. 2001;82:674-682.
42. Uchida K. 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog Lipid Res. 2003;42:318-343.
43. Belkhiri A, Richards C, Whaley M, McQueen SA, Orr FW. Increased expression of activated MMP-2 by human endothelial cells after sublethal H2O2 exposure. Lab Invest. 1997;77:533-539.
44. Yoon SO, Park SJ, Yoon SY, Yun CH, Chung AS. Sustained production of H2O2 activates pro-MMP-2 through receptor tyrosine kinases/phosphatidylinositol 3-kinase/NF-kB pathway. J Biol Chem. 2002;277:30271-30282.
45. Kheradmand F, Rishi K, Werb Z. Signaling through the EGF receptor controls lung morphogenesis in part by regulating MT1-MMP-mediated activation of gelatinase A/MMP2. J Cell Sci. 2002;115:839-848.
46. Suc I, Escargueil-Blanc I, Troly M, Salvayre R, Negre-Salvayre A. HDL and ApoA prevent cell death of endothelial cells induced by oxidized LDL. Arterioscler Thromb Vasc Biol. 1997;17:2158-2166.
47. Auge N, Garcia V, Maupas-Schwalm F, Levade T, Salvayre R, Negre-Salvayre A. Oxidized LDL-induced smooth muscle cell proliferation involves the EGF receptor/PI-3 kinase/Akt and the sphingolipid signaling pathways. Arterioscler Thromb Vasc Biol. 2002;22:1990-1995.